Top

Published in:

06-07-2021 | Sarcoidosis | Original Article

Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis

Authors: Munehisa Bekki, MD, Nobuhiro Tahara, MD, PhD, Atsuko Tahara, MD, Yoichi Sugiyama, MD, PhD, Shoko Maeda-Ogata, MD, Akihiro Honda, MD, PhD, Sachiyo Igata, MD, Mika Enomoto, MD, PhD, Tatsuyuki Kakuma, MPH, PhD, Hayato Kaida, MD, PhD, Toshi Abe, MD, PhD, Yoshihiro Fukumoto, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 5/2022

Abstract

Background

The localization of myocardial 18F-fluorodeoxyglucose (FDG) uptake affecting long-term clinical outcomes has not been elucidated in patients with corticosteroid-naïve cardiac sarcoidosis (CS).

Objectives

This study sought to investigate the localization of myocardial FDG uptake on positron emission tomography (PET) and myocardial perfusion abnormality to predict adverse events (AEs) for a long-term follow-up in patients with corticosteroid-naïve CS.

Methods

Consecutive 90 patients with clinical suspicion of CS who underwent FDG-PET imaging to assess for inflammation were enrolled. AEs were defined as a composite of sustained ventricular tachycardia (VT), heart transplantation, and all-cause death, which were ascertained by medical records, defibrillator interrogation, and telephone interviews.

Results

Of 90 patients, 42 patients (mean age 62.9 ± 12.0 years; 76.2% females) were confirmed active cardiac involvement. Over a median follow-up of 4.9 years, 15 patients with CS experienced AEs including 6 sustained ventricular tachycardias (VT) and 9 deaths. Cox proportional-hazards model after adjustment for left ventricular systolic dysfunction revealed that FDG uptake in the right ventricle (RV) or basal anterolateral area of the left ventricle (LV) with myocardial perfusion abnormality was predictive of AEs.

Conclusions

FDG uptake in the RV or basal anterolateral area of the LV with myocardial perfusion abnormality provides long-term prognostic risk stratification in patients with corticosteroid-naïve CS.

Available only for authorised users

Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: Influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121:32-39CrossRef

Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68:411-21CrossRef

Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al; Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10

Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005; 95:143-46CrossRef

Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010; 3:1219-28CrossRef

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63:329-36CrossRef

Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018; 11:336-45CrossRef

Flores RJ, Flaherty KR, Jin Z, Bokhari S. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol 2020; 27:2003-10CrossRef

Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al; IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-74

10.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR Revised equations for estimated. GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982-92CrossRef

11.

Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26:1538-43CrossRef

12.

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-55

13.

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53:241-48CrossRef

14.

Haga Y, Ishii K, Suzuki T. N-glycosylation is critical for the stability and intracellular trafficking of glucose transporter GLUT4. J Biol Chem 2011; 286:31320-27CrossRef

15.

Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010; 195:310-20CrossRef

16.

Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol 2009; 104:571-77CrossRef

17.

Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990; 31:1749-56PubMed

18.

Lapa C, Reiter T, Kircher M, Schirbel A, Werner RA, Pelzer T et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: An initial comparison to cardiac MRI. Oncotarget 2016; 7:77807-14CrossRef

19.

Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1305-23CrossRef

20.

Wu YW, Naya M, Tsukamoto T, Komatsu H, Morita K, Yoshinaga K et al. Heterogeneous reduction of myocardial oxidative metabolism in patients with ischemic and dilated cardiomyopathy using C-11 acetate PET. Circ J 2008; 72:786-92CrossRef

21.

Lindner O, Vogt J, Baller D, Kammeier A, Wielepp P, Holzinger J et al. Global and regional myocardial oxygen consumption and blood flow in severe cardiomyopathy with left bundle branch block. Eur J Heart Fail 2005; 7:225-30CrossRef

Title: Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis
Authors: Munehisa Bekki, MD
Nobuhiro Tahara, MD, PhD
Atsuko Tahara, MD
Yoichi Sugiyama, MD, PhD
Shoko Maeda-Ogata, MD
Akihiro Honda, MD, PhD
Sachiyo Igata, MD
Mika Enomoto, MD, PhD
Tatsuyuki Kakuma, MPH, PhD
Hayato Kaida, MD, PhD
Toshi Abe, MD, PhD
Yoshihiro Fukumoto, MD, PhD
Publication date: 06-07-2021
Publisher: Springer International Publishing
Keywords: Sarcoidosis
Sarcoidosis
Ventricular Tachycardia
Positron Emission Tomography
Published in: Journal of Nuclear Cardiology / Issue 5/2022
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-021-02684-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis

Abstract

Background

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2022

Abstracts of Original Contributions ASNC2022 The 27th Annual Scientific Session of the American Society of Nuclear Cardiology

Diagnostic safety of a machine learning-based automatic patient selection algorithm for stress-only myocardial perfusion SPECT

Clinical implications of compromised 82Rb PET data acquisition

Effect of iterations and time of flight on normal distributions of 82Rb PET relative perfusion and myocardial blood flow

Identifying CRT responders: Moving from electrical to mechanical dyssynchrony

Complementary role of hybrid imaging with SPECT myocardial perfusion and coronary CT angiography in hypertrophic cardiomyopathy